Heart-Kidney Biomarkers in Patients Undergoing Cardiac Stress Testing

Table 3

Results between groups based on existence of detectable plasma neutrophil gelatinase-associated lipocalin (NGAL).

Study variable	Detectable NGAL (𝑛=23)	No detectable NGAL (𝑛=11)	P value
Laboratory
Creatinine (𝜇mol/L)—at rest	84.0±25.2	75.1±17.5	.24
Creatinine (𝜇mol/L)—with stress	87.4±26.0	75.9±19.4	.16
ΔCreatinine (𝜇mol/L)	3.3±8.1	0.8±6.1	.32
BNP (pg/mL)—at rest	73.8±57.6	53.9±46.7	.29
BNP (pg/mL)—with stress	84.0±64.3	57.5±44.0	.17
ΔBNP (pg/mL)	10.2±11.9	3.5±4.8	.03
cTnI (𝜇g/L)—at rest	0.010±0.009	0.006±0.003	.05
cTnI (𝜇g/L)—with stress	0.013±0.010	0.012±0.016	.86
ΔcTnI (𝜇g/L)	0.003±0.007	0.007±0.015	.39
NT-proBNP (pg/mL)—at rest	511.0±642.0	303.1±258.0	.19
NT-proBNP (pg/mL)—with stress	556.3±685.6	312.1±226.5	.13
ΔNT-proBNP (pg/mL)	45.4±83.2	9.0±46.0	.11
AOPP (𝜇mol/L)—at rest	105.7±102.0	89.3±52.8	.54
AOPP (𝜇mol/L)—with stress	85.8±91.1	71.1±24.7	.48
ΔAOPP (𝜇mol/L)	−19.9±41.9	−18.2±38.6	.91
Cardiovascular parameters
Segmental perfusion defects—at rest	3.8±5.3	0.9±2.1	.03
Segmental perfusion defects—with stress	8.2±8.0	4.2±3.7	.06
ΔSegmental perfusion defects	4.1±3.8	3.3±3.3	.51
End diastolic volume (mL)—at rest	108.4±25.9	90.8±31.7	.14
End diastolic volume (mL)—with stress	112.8±32.5	90.2±27.9	.05
ΔEnd diastolic volume (mL)	4.8±11.2	0.8±8.0	.25
End systolic volume (mL)—at rest	49.9±21.5	34.7±20.1	.07
End systolic volume (mL)—with stress	53.5±27.5	34.4±18.0	.02
ΔEnd systolic volume (mL)	3.6±9.4	1.1±7.4	.44
Ejection fraction (%)—at rest	55.8±10.6	65.0±10.7	.03
Ejection fraction (%)—with stress	55.1±11.0	63.8±10.3	.04
ΔEjection fraction (%)	−0.7±5.1	−1.2±4.9	.78

Δ: delta (change from prestress to poststress test).
BNP: B-type natriuretic peptide, cTnI: cardiac troponin I, NT-proBNP: N-terminal-pro-B-type natriuretic peptide, AOPP: advanced oxidation protein products, NGAL: neutrophil gelatinase-associated lipocalin.